Current report filing

Note 20 - Agreements (Details Textual)

v3.8.0.1
Note 20 - Agreements (Details Textual)
 1 Months Ended 12 Months Ended
Mar. 03, 2017
$ / shares
shares
Jul. 31, 2014
USD ($)
Sep. 30, 2013
USD ($)
Aug. 31, 2013
May 31, 2013
Jul. 31, 2012
USD ($)
shares
Dec. 31, 2011
USD ($)
Nov. 30, 2009
Apr. 30, 2008
USD ($)
Jan. 31, 2002
USD ($)
Dec. 31, 2016
USD ($)
$ / shares
Dec. 31, 2015
USD ($)
$ / shares
Dec. 31, 2014
USD ($)
Common Stock, Par or Stated Value Per Share | $ / shares                     $ 0.001 $ 0.001  
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares [1]                     $ 0.33    
Research and Development Expense                     $ 7,138,080 $ 10,562,729 $ 15,116,978
Minimum [Member]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                     $ 0.01    
Maximum [Member]                          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares                     $ 3.04    
Subsequent Event [Member]                          
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.001                        
Subsequent Event [Member] | Series NN Warrants [Member] | UCSD [Member]                          
Class of Warrant or Right, Term 5 years                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 1,000,000                        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.50                        
Reliable Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term               10 years          
Long-term Contract for Supplies, Option to Extend, Term               3 years          
Long-term Contract for Supplies, Resolution Term               60 days          
Purchases Under Manufacture and Supply Agreement                     $ 1,100,000 225,000 300,000
Purchase Orders Issued                     525,000    
Agreement Expiration Date               2019-11          
Nordion Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term         3 years                
Purchases Under Clinical Supply Agreement                     43,000 244,000 505,000
Agreement Expiration Date         2016-05                
PETNET Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term       3 years                  
Purchases Under Manufacturing Agreement                     826,000 855,000 2,200,000
Agreement Expiration Date       2016-08                  
OsoBio Supply Agreement [Member]                          
Long-term Contract for Supplies, Resolution Term     60 days                    
Purchase Orders Issued     $ 562,000                    
Purchases Under Manufacturing Agreement                     1,200,000 472,000 96,000
Gipharma Supply Agreement [Member]                          
Long-term Contract for Supplies, Initial Term     3 years                    
Long-term Contract for Supplies, Resolution Term     30 years                    
Purchase Orders Issued                     1,500    
Long-term Contract for Supplies, Renewal Term     1 year                    
Long-term Contract for Supplies, Notice Period Prior to Automatic Renewal     180 days                    
Long-term Contract for Supplies, Notice Period     60 days                    
Purchases Under Service and Supply Master Agreement                     149,000 677,000 272,000
Tc99m Tilmanocept License Agreement [Member]                          
License Issue Fee                   $ 25,000      
License Maintenance Fee                   25,000      
Minimum Annual Royalty                   $ 25,000      
Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | Cost of Sales [Member]                          
License Costs                     2,000 1,000 1,000
Expanded Tc99m Tilmanocept License Agreement [Member]                          
License Issue Fee                 $ 25,000        
License Maintenance Fee                 25,000        
Minimum Annual Royalty                 $ 25,000        
Research and Development Expense   $ 25,000                      
Tilmanocept License Agreement [Member]                          
License Issue Fee   25,000                      
License Maintenance Fee   25,000                      
Minimum Annual Royalty   $ 25,000                      
Research and Development Expense                     199,000 152,000 25,000
Astra Zeneca Agreement [Member]                          
License Costs             $ 5,000,000            
Research and Development Expense                     $ 116,000 80,000 81,000
Milestone Payments, Maximum, Cash, Clinical Development and Regulatory Filing Milestones             6,500,000            
Milestone Payments, Maximum, Cash, Due Following Receipt of Regulatory Approvals and Initiation of Commercial Sales             $ 11,000,000            
Alseres Pharmaceuticals Agreement [Member]                          
Research and Development Expense                       $ 5,000 $ 42,000
Sublicense Execution Payment, Cash Paid           $ 175,000              
Stock Issued During Period, Shares Issued for Sublicense Fee | shares           300,000              
Milestone Payments, Maximum, Cash           $ 2,900,000              
Milestone Payments, Maximum, Cash, At the Time of Product Registration or Upon Commercial Sales           $ 2,500,000              
Stock Issued During Period, Shares Issued or Issuable for Sublicense Fee | shares           1,150,000              
Stock Issued During Period, Shares Issued or Issuable for Sublicense Fee, At the Time of Product Registration or Upon Commercial Sales | shares           950,000              
Employment Agreement [Member] | Minimum [Member]                          
Ratio of Entitled Salary                     1.3    
Employment Agreement [Member] | Maximum [Member]                          
Ratio of Entitled Salary                     2.75    
Loss Contingency, Estimate of Possible Loss                     $ 1,900,000    
[1] Weighted average exercise price.